Aclarion’s (ACON) “Buy” Rating Reaffirmed at Ascendiant Capital Markets

Aclarion (NASDAQ:ACON)‘s stock had its “buy” rating reissued by equities research analysts at Ascendiant Capital Markets in a research report issued on Monday, Stock Target Advisor reports. They presently have a $1.50 target price on the stock.

Aclarion Trading Up 4.8 %

Shares of ACON stock opened at $0.24 on Monday. The company has a fifty day moving average price of $0.28 and a two-hundred day moving average price of $0.42. Aclarion has a one year low of $0.20 and a one year high of $9.90.

Aclarion (NASDAQ:ACON) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. Aclarion had a negative return on equity of 2,554.98% and a negative net margin of 10,246.33%. The firm had revenue of $0.01 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC acquired a new stake in Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 1.40% of Aclarion as of its most recent SEC filing. 7.52% of the stock is owned by institutional investors.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.